[96a5a0]: / output / chiaCancer / identified / NCT02145026_identified.json

Download this file

317 lines (317 with data), 13.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
{
"info": {
"nct_id": "NCT02145026",
"official_title": "A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)",
"inclusion_criteria": "* Adult participants with low or intermediate-1 risk MDS\n* No previous treatment with hematopoietic growth factors within 3 months prior to screening\n* Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator\n* Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment\n* Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening\n* Clinically stable for at least 1 month prior to entry into the study\n* For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment\n* Poorly controlled hypertension as assessed by the investigator\n* History of Acute Myeloid Leukemia (AML) or high risk for AML\n* Administration of another investigational drug within 1 month before screening or planned during the study period\n* Previously documented evidence of Pure Red Cell Aplasia (PRCA)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Adult participants with low or intermediate-1 risk MDS",
"criterions": [
{
"exact_snippets": [
"Adult participants"
],
"criterion": "age",
"requirement_type": "category",
"expected_value": "adult"
},
{
"exact_snippets": [
"low or intermediate-1 risk MDS"
],
"criterion": "MDS risk",
"requirement_type": "category",
"expected_value": [
"low",
"intermediate-1"
]
}
]
},
{
"line": "* No previous treatment with hematopoietic growth factors within 3 months prior to screening",
"criterions": [
{
"exact_snippets": [
"No previous treatment with hematopoietic growth factors"
],
"criterion": "hematopoietic growth factors",
"requirement_type": "previous treatment",
"expected_value": false
},
{
"exact_snippets": [
"within 3 months prior to screening"
],
"criterion": "time since last treatment with hematopoietic growth factors",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3
}
]
}
}
]
},
{
"line": "* Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator",
"criterions": [
{
"exact_snippets": [
"Symptomatic anemia"
],
"criterion": "anemia",
"requirement_type": "symptom presence",
"expected_value": true
},
{
"exact_snippets": [
"hemoglobin <10 g/dL"
],
"criterion": "hemoglobin",
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 10
}
}
]
},
{
"line": "* Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment",
"criterions": [
{
"exact_snippets": [
"Serum erythropoietin <500 milliunits/milliliter (mU/mL)"
],
"criterion": "serum erythropoietin",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 500
}
]
}
}
]
},
{
"line": "* Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening",
"criterions": [
{
"exact_snippets": [
"no red blood cell transfusion"
],
"criterion": "red blood cell transfusion",
"requirement_type": "absence",
"expected_value": true
},
{
"exact_snippets": [
"dependent on <4 units within 8 weeks prior to screening"
],
"criterion": "red blood cell transfusion",
"requirement_type": "dependency",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 4
}
]
}
}
]
},
{
"line": "* Clinically stable for at least 1 month prior to entry into the study",
"criterions": [
{
"exact_snippets": [
"Clinically stable for at least 1 month"
],
"criterion": "clinical stability",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1
}
]
}
}
]
},
{
"line": "* For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception",
"criterions": [
{
"exact_snippets": [
"female participants of childbearing potential"
],
"criterion": "female participants",
"requirement_type": "childbearing potential",
"expected_value": true
},
{
"exact_snippets": [
"male participants with partners of childbearing potential"
],
"criterion": "male participants",
"requirement_type": "partners' childbearing potential",
"expected_value": true
},
{
"exact_snippets": [
"agreement (by participants and/or partner) to use highly effective form(s) of contraception"
],
"criterion": "contraception",
"requirement_type": "agreement to use",
"expected_value": true
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "volunteer health status",
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
}
],
"exclusion_lines": [
{
"line": "* Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment",
"criterions": [
{
"exact_snippets": [
"Contraindications",
"to the active substance and/or any of the excipients of epoetin beta treatment"
],
"criterion": "contraindications",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"known hypersensitivity",
"to the active substance and/or any of the excipients of epoetin beta treatment"
],
"criterion": "hypersensitivity",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* Poorly controlled hypertension as assessed by the investigator",
"criterions": [
{
"exact_snippets": [
"Poorly controlled hypertension"
],
"criterion": "hypertension",
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
},
{
"line": "* History of Acute Myeloid Leukemia (AML) or high risk for AML",
"criterions": [
{
"exact_snippets": [
"History of Acute Myeloid Leukemia (AML)"
],
"criterion": "Acute Myeloid Leukemia (AML)",
"requirement_type": "history",
"expected_value": true
},
{
"exact_snippets": [
"high risk for AML"
],
"criterion": "Acute Myeloid Leukemia (AML)",
"requirement_type": "risk",
"expected_value": "high"
}
]
},
{
"line": "* Administration of another investigational drug within 1 month before screening or planned during the study period",
"criterions": [
{
"exact_snippets": [
"Administration of another investigational drug"
],
"criterion": "investigational drug",
"requirement_type": "administration",
"expected_value": true
},
{
"exact_snippets": [
"within 1 month before screening"
],
"criterion": "investigational drug administration",
"requirement_type": "timeframe",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1
}
]
}
}
]
},
{
"line": "* Previously documented evidence of Pure Red Cell Aplasia (PRCA)",
"criterions": [
{
"exact_snippets": [
"Previously documented evidence of Pure Red Cell Aplasia (PRCA)"
],
"criterion": "Pure Red Cell Aplasia (PRCA)",
"requirement_type": "documentation",
"expected_value": true
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}